BioNexus Gene Lab Corp. (BGLC)

BioNexus Gene Lab Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	9.78	9.77	10.93	13.36	11.39	0.13
Revenue Growth (YoY)	-4.88%	-10.60%	-18.21%	17.31%	8872.03%	-40.21%
Cost of Revenue	8.47	8.44	9.67	11.17	9.67	0.07
Gross Profit	1.31	1.33	1.26	2.19	1.72	0.06
Selling, General & Admin	4.5	4.41	1.73	1.2	1.33	0.36
Other Operating Expenses	0.48	0	-0.18	-0.07	-0.89	-0.03
Operating Expenses	4.13	3.92	1.55	1.14	0.45	0.33
Operating Income	-2.82	-2.59	-0.29	1.06	1.27	-0.28
Interest Income	-0	0	0.01	0.01	0.01	0
Interest Expense	0.02	0.01	0.01	0.01	0.01	0
Other Expense / Income	-0.2	-	0.01	0.01	0.01	-
Pretax Income	-2.64	-2.61	-0.3	1.04	1.26	-0.28
Income Tax	0.03	0.02	0.05	0.29	0.17	-0.03
Net Income	-2.66	-2.63	-0.36	0.75	1.09	-0.25
Net Income Growth	-	-	-	-31.31%	-	-
Shares Outstanding (Basic)	18	16	14	14	9	7
Shares Outstanding (Diluted)	18	16	14	14	9	7
Shares Change	22.04%	10.17%	0.99%	66.36%	19.16%	30.20%
EPS (Basic)	-0.17	-0.17	-0.02	0.05	0.13	-0.03
EPS (Diluted)	-0.17	-0.17	-0.02	0.05	0.13	-0.03
EPS Growth	-	-	-	-59.46%	-	-
Free Cash Flow	-1.38	-1.45	0.49	0.01	0.13	-0.23
Free Cash Flow Per Share	-0.08	-0.09	0.03	0.00	0.02	-0.03
Gross Margin	13.35%	13.61%	11.52%	16.42%	15.10%	44.02%
Operating Margin	-28.89%	-26.54%	-2.66%	7.90%	11.18%	-217.17%
Profit Margin	-27.25%	-26.91%	-3.26%	5.62%	9.61%	-194.14%
Free Cash Flow Margin	-14.15%	-14.85%	4.48%	0.04%	1.15%	-181.24%
Effective Tax Rate	-	-	-	27.93%	13.34%	-
EBITDA	-2.71	-2.49	-0.19	1.16	1.38	-0.22
EBITDA Margin	-27.73%	-25.43%	-1.70%	8.71%	12.08%	-175.16%
Depreciation & Amortization	0.11	0.11	0.11	0.11	0.1	0.05
EBIT	-2.82	-2.59	-0.29	1.06	1.27	-0.28
EBIT Margin	-28.89%	-26.54%	-2.66%	7.90%	11.18%	-217.17%

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.